UNSPSC 51172129: Fenoverine

This classification denotes an antispasmotic agent with the molecular formula C26H25N3O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N274ZQ6PZJ, chemically known as 10h-phenothiazine, 10-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)acetyl)- but generally known as fenoverine, which bears US NIH Compound Identifier 72098. European Medicines Agency schedules Fenoverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07580MIG.

UNSPSC 51172129 Fenoverine is a Commodity code that encompasses pharmaceutical products and related testing services as solicited by state and local government bodies. Recent state and local opportunities tagged to this code show a divergence in scope: while the code nominally refers to a specific pharmaceutical substance, the actual procurement activity includes broad-based drug testing services, pharmaceutical supply agreements, and pharmacy benefit program initiatives. Collin County Community Supervision and Corrections Department is soliciting offender specimen collection and drug testing services under RFP 2026-327, due July 23, 2026, with an estimated contract value of $600,000 over two years plus optional renewals, encompassing immunoassay screening with confirmation methodologies, electronic reporting, and lab certification compliance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is procuring generic multi-source pharmaceuticals and OTC products through an RFP with proposals due March 26, 2026, requiring vendors to supply through authorized wholesalers with comprehensive pricing for identified NDCs and compliance with cGMP and Drug Supply Chain Security Act standards. The Texas Health and Human Services Commission has issued an RFI for vendor capabilities around direct-to-manufacturer prescription programs, posted April 3, 2026, as a preliminary market intelligence phase to inform future procurement strategy. Issuing bodies across these opportunities include county corrections departments, multistate cooperative purchasing alliances administered by state procurement offices, and state health and human services commissions.

Recent activity centers on Texas and Minnesota. The Collin County opportunity reflects county-level corrections procurement in North Texas, while MMCAP represents a multistate cooperative vehicle serving participating state and local facilities across Oregon and Minnesota. The Texas HHS RFI signals emerging state-level interest in direct pharmacy contracting models outside traditional PBM and GPO channels. The code shows modest recent activity across these three distinct procurement streams—corrections-based drug testing, multistate pharmaceutical supply, and state pharmacy benefit initiatives—rather than concentrated volume under a single issuing body or jurisdiction. Collin County's RFP emphasizes staffing and testing operations at two North Texas collection sites with annual testing demand of approximately 25,031 tests priced on a per-test basis; MMCAP's RFP requires products available by May 15, 2026 with July 1, 2026 effective dates and a two-year contract term; and the Texas HHS RFI remains in exploratory phase with no formal award timeline or budget disclosed.